Skip to main content

PredictImmune Expands Licensing Deal With Cambridge Enterprise

NEW YORK – PredictImmune announced today an expansion of a worldwide licensing agreement to allow the UK firm first right of refusal to new technologies from Cambridge Enterprise.

The expanded deal grants PredictImmune right of first refusal to technology allowing for the prediction of disease outcome for systemic lupus erythematosus as a follow-on disease, the Cambridge, UK-based company said. A prior deal between the partners covered technology related to the prediction of disease outcome in relapsing-remitting autoimmune and inflammatory disease, specifically for inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

PredictImmune added that the new terms will allow the company to "evolve" its product line and hasten its products into this new therapeutic space.

Financial and other details of the deal were not disclosed.